

Supplementary Online Content

Aljehani MA, Morgan JW, Guthrie LA, et al. Association of primary tumor site with mortality in patients receiving bevacizumab and cetuximab for metastatic colorectal cancer. *JAMA Surg*. Published online September 20, 2017.
doi:10.1001/jamasurg.2017.3466

eTable 1. Adjusted Hazard Ratios for Tumor Origin by Treatment Type (n = 11 269)

eTable 2. Interaction between Tumor Origin and Selected Treatment Type on Mortality Hazards for Metastatic Colorectal Cancer

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Adjusted Hazard Ratios for Tumor Origin by Treatment Type (n = 11 269)^a

Tumor Origin	SC alone	SC + Bevacizumab	SC + Cetuximab
Right-Sided	1 (Reference)	0.94 (0.89-0.99) <i>P</i> = .026	1.40 (1.14-1.70) <i>P</i> < .0001
Left-Sided	1 (Reference)	0.89 (0.86-0.93) <i>P</i> < .0001	0.83 (0.76-0.96) <i>P</i> = .007

Abbreviations: SC, systemic chemotherapy; HR, hazard ratio; CI, confidence interval.

^a Hazard ratios adjusted for age, diagnosis year, mucinous, signet ring, and social economic status using propensity score.

eTable 2. Interaction Between Tumor Origin and Selected Treatment Type on Mortality Hazards for Metastatic Colorectal Cancer

Tumor Origin	Treatment Types		HR (95% CI) for treatment types within strata of tumor origin
	SC+Bevacizumab HR ^a (95% CI)	SC+Cetuximab HR ^a (95% CI)	
(A) All subjects treated with BT, 2004-2014 (n=4,383)			
Right-sided	1.33 (1.28-1.39) <i>P</i> <.0001	2.10 (1.84-2.39) <i>P</i> <.0001	1.56^b (1.37-1.78) <i>P</i> <.0001
Left-sided	1 (Reference)	0.97 (0.89-1.06) <i>P</i> =.51	0.97^c (0.89-1.06) <i>P</i> =.51
HR (95% CI) for Right vs Left within strata of treatment types			
	1.33^c (1.28-1.39) <i>P</i> <.0001	2.28^d (1.92-2.70) <i>P</i> <.0001	
(B) KRAS wild-type subjects treated with BT, 2010-2014 (n=628)			
Right-sided	1.59 (1.39-1.83) <i>P</i> <.0001	2.82 (2.13-3.73) <i>P</i> <.0001	1.80^b (1.35-2.42) <i>P</i> <.0001
Left-sided	1 (Reference)	0.75 (0.63-0.90) <i>P</i> =.002	0.75^c (0.63-0.90) <i>P</i> =.002
HR (95% CI) for Right vs Left within strata of treatment types			
	1.59^c (1.39-1.83) <i>P</i> <.0001	3.19^d (2.30-4.42) <i>P</i> <.0001	

Abbreviations: SC, systemic chemotherapy; HR, hazard ratio; CI, confidence interval; BT, biologic therapy;

^a HR adjusted for age, diagnosis year, mucinous, signet ring, and social economic for part status using propensity score (A) and HR adjusted for age, diagnosis year, and social economic for part status using propensity score (B).

^b Referent category is right-sided treated with SC and bevacizumab.

^c Referent category is left-sided treated with SC and bevacizumab.

^d Referent category is left-sided treated with SC and cetuximab.